BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
Completed
- Conditions
- Non-metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 870
- Registration Number
- NCT05362149
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
Completed
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1602
- Registration Number
- NCT05350189
- Locations
- 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants
Phase 1
Completed
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenHealthy VolunteersHot Flashes
- Interventions
- Drug: Elinzanetant (BAY3427080)
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT05351892
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Phase 4
Recruiting
- Conditions
- Non-metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT05348876
- Locations
- 🇮🇳
HCG Oncology Center, Bengaluru, Karnataka, India
🇮🇳Tata Memorial Hospital, Mumbai, Maharashtra, India
🇮🇳MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, Andhra Pradesh, India
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4500
- Registration Number
- NCT05348733
- Locations
- 🇺🇸
Nephrology Consultants LLC, Huntsville, Alabama, United States
🇺🇸AKDHC Medical Research Servies LLC, Phoenix, Arizona, United States
🇺🇸Harrisburg Family Medical Center, Harrisburg, Arkansas, United States
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Terminated
- Conditions
- Metastatic Castration-resistant Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT05301062
- Locations
- 🇨🇳
Many locations, Multiple Locations, China
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1664
- Registration Number
- NCT05254002
- Locations
- 🇨🇦
Recherche GCP Research, Montreal, Quebec, Canada
🇺🇸Southwest Kidney Institute, PLC, Surprise, Arizona, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
Completed
- Conditions
- Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene FusionInfantile Fibrosarcoma
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 93
- Registration Number
- NCT05236257
- Locations
- 🇫🇷
Multiple Locations, Multiple Locations, France
A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain
Phase 2
Completed
- Conditions
- Peripheral Neuropathic PainNeuropathic Pain Associated With Diabetic Peripheral NeuropathyDiabetes Mellitus
- Interventions
- Drug: Placebo for BAY2395840
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT05219812
- Locations
- 🇩🇪
InnoDiab Forschung GmbH, Essen, Nordrhein-Westfalen, Germany
🇬🇧MAC Research Centre - Manchester, Manchester, United Kingdom
🇩🇪Klinische Forschung Hannover-Mitte GmbH, Hannover, Niedersachsen, Germany
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
Completed
- Conditions
- Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT05217914
- Locations
- 🇨🇳
Many Locations, Multiple Locations, Taiwan
© Copyright 2025. All Rights Reserved by MedPath